<DOC>
	<DOCNO>NCT01114737</DOCNO>
	<brief_summary>This double-blind , placebo-controlled , randomize study design evaluate safety therapeutic effect sapropterin dihydrochloride neuropsychiatric symptom subject PKU .</brief_summary>
	<brief_title>Safety Therapeutic Effects Sapropterin Dihydrochloride Neuropsychiatric Symptoms Phenylketonuria ( PKU ) Patients</brief_title>
	<detailed_description>Phenylketonuria ( PKU ) result deficient phenylalanine hydroxylase ( PAH ) activity lead toxic phenylalanine ( Phe ) accumulation patient PKU cause mental retardation , microcephaly , delay speech , seizure , psychiatric symptom behavioral abnormality . Although PKU patient early initiation dietary treatment prevents severe complication , discontinuation dietary restriction early age associate poor cognitive development neuropsychiatric disorder present even early-treated well control PKU patient . This study , PKU-016 , conduct PKU patient evaluate therapeutic effect sapropterin dihydrochloride symptom attention deficit hyperactivity disorder ( ADHD ) , depression , anxiety .</detailed_description>
	<mesh_term>Phenylketonurias</mesh_term>
	<mesh_term>Verapamil</mesh_term>
	<criteria>≥ 8 year age Confirmed diagnosis PKU Willing continue current diet ( typical diet 3 month prior study entry ) unchanged participate study Willing able provide write , sign inform consent case subject age 18 , provide write assent ( require ) write informed consent legally authorize representative nature study explain , prior researchrelated procedure Sexually active subject must willing use acceptable method contraception participate study least 30 day follow last dose sapropterin dihydrochloride Females childbearing potential must negative pregnancy test screen willing additional pregnancy test study . Females consider childbearing potential include menopause least 2 year , tubal ligation least 1 year prior screening , total hysterectomy . Willing able comply study procedure Has know hypersensitivity sapropterin dihydrochloride excipients Subject breastfeed screen plan become pregnant ( subject partner ) time study Use investigational product investigational medical device within 30 day prior screen , requirement investigational agent prior completion schedule study assessment Received sapropterin dihydrochloride within 16 week randomization Have initiate adjusted medication treatment ADHD , depression , anxiety ≤ 8 week prior randomization Taking medication know inhibit folate synthesis ( eg , methotrexate ) Any condition require treatment levodopa PDE5 inhibitor Concurrent disease condition would interfere study participation , compliance safety determine Investigator Any condition , view Investigator , place subject high risk poor treatment compliance completing study</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Phenylketonuria</keyword>
	<keyword>PKU</keyword>
	<keyword>Kuvan</keyword>
	<keyword>Sapropterin dihydrochloride</keyword>
	<keyword>Neuropsychiatric disorder</keyword>
	<keyword>ADHD</keyword>
</DOC>